Lakefront Biotherapeutics NV (LKFT)

Market Cap	2.02B +8.8%
Revenue (ttm)	1.20B +262.2%
Net Income	563.56M
EPS	8.55
Shares Out	65.90M
PE Ratio	3.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,200
Open	30.55
Previous Close	30.35
Day's Range	30.33 - 30.86
52-Week Range	26.42 - 37.78
Beta	0.12
Analysts	Sell
Price Target	22.95 (-25.02%)
Earnings Date	Aug 10, 2026

About LKFT

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 558
• Stock Exchange: NASDAQ
• Ticker Symbol: LKFT
• Website: https://lakefrontbio.com

Financial Performance

In 2025, LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for LKFT stock is "Sell." The 12-month stock price target is $22.95, which is a decrease of -25.02% from the latest price.

Price Target

$22.95

(-25.02% downside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 8, 2026

Data Sources Report a data error